{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:55:06Z","timestamp":1790963706617,"version":"4.1.0"},"reference-count":91,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T00:00:00Z","timestamp":1253750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Despite setbacks to the approval of new medications for the treatment of irritable bowel syndrome, interim guidelines on endpoints for irritable bowel syndrome (IBS) trials have enhanced interest as new targets for medical therapy are proposed based on novel mechanisms or chemical entities.<\/jats:p><jats:p><jats:bold>Aims\u2002<\/jats:bold> To review the approved lubiprostone, two targets that are not meeting expectations (tachykinins and corticotrophin\u2010releasing hormone), the efficacy and safety of new 5\u2010HT<jats:sub>4<\/jats:sub> agonists, intestinal secretagogues (chloride channel activators, and guanylate cyclase\u2010C agonists), bile acid modulation, anti\u2010inflammatory agents and visceral analgesics.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Review of selected articles based on PubMed search and clinically relevant information on mechanism of action, safety, pharmacodynamics and efficacy.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The spectrum of peripheral targets of medical therapy addresses chiefly the bowel dysfunction of IBS and these effects are associated with pain relief. The pivotal mechanisms responsible for the abdominal pain or visceral sensation in IBS are unknown. The new 5\u2010HT<jats:sub>4<\/jats:sub> agonists are more specific than older agents and show cardiovascular safety to date. Secretory agents have high specificity, low bioavailability and high efficacy. The potential risks of agents \u2018borrowed\u2019 from other indications (such as hyperlipidaemia, inflammatory bowel disease or somatic pain) deserve further study.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> There is reason for optimism in medical treatment of IBS with a spectrum of agents to treat bowel dysfunction. However, visceral analgesic treatments are still suboptimal.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2009.04153.x","type":"journal-article","created":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T14:12:58Z","timestamp":1253801578000},"page":"35-46","source":"Crossref","is-referenced-by-count":42,"title":["Review article: new receptor targets for medical therapy in irritable bowel syndrome"],"prefix":"10.1111","volume":"31","author":[{"given":"M.","family":"CAMILLERI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"e_1_2_15_2_2","first-page":"S1","article-title":"An evidence\u2010based systematic review on the management of irritable bowel syndrome","volume":"10","author":"Brandt LJ","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_15_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.005"},{"key":"e_1_2_15_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.12.1653"},{"key":"e_1_2_15_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aep125"},{"key":"e_1_2_15_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70109-3"},{"key":"e_1_2_15_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)85527-4"},{"key":"e_1_2_15_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.00934.x"},{"key":"e_1_2_15_9_2","first-page":"A60","article-title":"Lack of effect of the NH3 receptor antagonist, talnetant SB223412, on symptoms of IBS: results of 2 randomized, double\u2010blind, placebo\u2010controlled dose\u2010ranging trials","volume":"132","author":"Dukes GE","year":"2007","journal-title":"Gastroenterology"},{"key":"e_1_2_15_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704217"},{"key":"e_1_2_15_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.6.845"},{"key":"e_1_2_15_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.018911"},{"key":"e_1_2_15_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04030.x"},{"key":"e_1_2_15_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.117549"},{"key":"e_1_2_15_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.00903.x"},{"key":"e_1_2_15_16_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00011.2009"},{"key":"e_1_2_15_17_2","first-page":"85","article-title":"The selective CRF\u20101 receptor antagonist GW876008 attenuates stress induced rectal hypersensitivity in patients with irritable bowel syndrome (IBS)","volume":"21","author":"Thoua NM","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"e_1_2_15_18_2","first-page":"84","article-title":"A randomised, double blind, placebo (PLA) controlled, crossover study to evaluate the efficacy and safety of the corticotrophin releasing factor 1 (CRF1) receptor antagonist (RA) GW876008 in irritable bowel syndrome (IBS) patients","volume":"21","author":"Duke GE","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"e_1_2_15_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02115.x"},{"key":"e_1_2_15_20_2","unstructured":"Pharmabiz. com.Forest to discontinue development in U.S. of dexloxiglumide for irritable bowel syndrome.2004. October. Available at:http:\/\/www.pharmabiz.com\/article\/detnews.asp?articleid=18255&sectionid=14(accessed 6 October 2009)."},{"key":"e_1_2_15_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41081.x"},{"key":"e_1_2_15_22_2","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(08)60730-1","article-title":"A phase III, 6\u2003month, double\u2010blind, placebo\u2010controlled, randomized withdrawal trial of the selective CCK 1 antagonist dexloxiglumide in constipation\u2010predominant IBS: the Darwin study","volume":"134","author":"Whorwell PJ","year":"2008","journal-title":"Gastroenterology"},{"key":"e_1_2_15_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.009"},{"key":"e_1_2_15_24_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00051.2008"},{"issue":"1","key":"e_1_2_15_25_2","first-page":"131","article-title":"Randomized, double\u2010blind, placebo (PLA)\u2010controlled, crossover study to evaluate efficacy and safety of the beta 3\u2010adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS)","volume":"20","author":"Kelleher DL","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"e_1_2_15_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.101675"},{"key":"e_1_2_15_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)70038-X"},{"key":"e_1_2_15_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.01059.x"},{"key":"e_1_2_15_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(91)90541-R"},{"key":"e_1_2_15_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21166"},{"key":"e_1_2_15_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800670"},{"key":"e_1_2_15_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03884.x"},{"key":"e_1_2_15_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.162404"},{"issue":"1","key":"e_1_2_15_34_2","first-page":"240","article-title":"A double\u2010blind, placebo controlled trial to evaluate the safety and tolerability of prucalopride oral solution in constipated elderly patients living in a nursing facility","volume":"136","author":"Camilleri M","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_15_35_2","first-page":"160","article-title":"Long\u2010term follow up of safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation","volume":"136","author":"Camilleri M","year":"2009","journal-title":"Gastroenterology"},{"key":"e_1_2_15_36_2","first-page":"A641","article-title":"ATI\u20107505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs","volume":"126","author":"Dennis D","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_15_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2006.00865.x"},{"issue":"1","key":"e_1_2_15_38_2","first-page":"158","article-title":"Efficacy of ATI\u20107505, a novel highly selective 5\u2010HT4 receptor agonist, in a rodent model","volume":"136","author":"Johnson AC","year":"2009","journal-title":"Gastroenterology"},{"key":"e_1_2_15_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-008-0282-y"},{"key":"e_1_2_15_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-008-0281-z"},{"issue":"2","key":"e_1_2_15_41_2","first-page":"6","article-title":"Dose\u2010related effects of TD\u20105108, a selective 5\u2010HT4 receptor agonist with high intrinsic activity, on gastrointestinal (GI) and colonic transit in healthy volunteers","volume":"20","author":"Camilleri M","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"e_1_2_15_42_2","first-page":"A547","article-title":"TD\u20105108, a selective 5\u2010HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation","volume":"133","author":"Goldberg MR","year":"2008","journal-title":"Gastroenterology"},{"key":"e_1_2_15_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-006-1537-1"},{"key":"e_1_2_15_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.01069.x"},{"key":"e_1_2_15_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000150632"},{"key":"e_1_2_15_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520802240255"},{"key":"e_1_2_15_47_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.09.031"},{"key":"e_1_2_15_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2008.01100.x"},{"issue":"1","key":"e_1_2_15_49_2","first-page":"237","article-title":"LX1031: a new approach for managing irritable bowel syndrome (IBS)","volume":"136","author":"Brown P","year":"2009","journal-title":"Gastroenterology"},{"key":"e_1_2_15_50_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.62.1.535"},{"key":"e_1_2_15_51_2","doi-asserted-by":"publisher","DOI":"10.1159\/000185719"},{"key":"e_1_2_15_52_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00528.2003"},{"key":"e_1_2_15_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.84"},{"key":"e_1_2_15_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2008.03.001"},{"key":"e_1_2_15_55_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00264.2005"},{"key":"e_1_2_15_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03629.x"},{"key":"e_1_2_15_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03881.x"},{"key":"e_1_2_15_58_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90558.2008"},{"key":"e_1_2_15_59_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014231722696"},{"key":"e_1_2_15_60_2","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.14309\/00000434-200410001-00863","article-title":"Antinociceptive actions of MD\u20101100, a novel therapeutic agent for C\u2010IBS, in animal models of visceral pain","volume":"99","author":"Bueno L","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_15_61_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.06.067"},{"key":"e_1_2_15_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.59"},{"key":"e_1_2_15_63_2","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.14309\/00000434-200809001-01179","article-title":"Linaclotide significantly improved abdominal pain, constipation and global assessments in adults with irritable bowel syndrome with constipation: results form a large twelve\u2010week, randomized, double\u2010blind, placebo\u2010controlled study","volume":"103","author":"Johnston J","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_15_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.22.2647"},{"key":"e_1_2_15_65_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106644"},{"key":"e_1_2_15_66_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107290"},{"key":"e_1_2_15_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.16.11.894"},{"key":"e_1_2_15_68_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00194.2001"},{"issue":"1","key":"e_1_2_15_69_2","first-page":"T1247","article-title":"Effects of chenodeoxycholic acid on gastrointestinal and colonic transit and bowel function in healthy volunteers","volume":"136","author":"Odunsi ST","year":"2009","journal-title":"Gastroenterology"},{"key":"e_1_2_15_70_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058301100211"},{"key":"e_1_2_15_71_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.15.3.165"},{"key":"e_1_2_15_72_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00388.x"},{"key":"e_1_2_15_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.16.1893"},{"key":"e_1_2_15_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.14.1531"},{"key":"e_1_2_15_75_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0283"},{"key":"e_1_2_15_76_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01438.x"},{"key":"e_1_2_15_77_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01288.x"},{"key":"e_1_2_15_78_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.02.074"},{"issue":"1","key":"e_1_2_15_79_2","first-page":"156","article-title":"Clinical benefit in IBS after disodium cromoglycate involves mast cell\u2010mediated recovery of healthy\u2010like innate immunity genes expression profile in the jejunal mucosa","volume":"136","author":"Lobo B","year":"2009","journal-title":"Gastroenterology"},{"key":"e_1_2_15_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.268"},{"key":"e_1_2_15_81_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.055"},{"key":"e_1_2_15_82_2","unstructured":"KlookerTK KoopmanKE HeideS WijngaardRM BoeckxstaensGETreatment with the mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in IBS patients. Proceedings of the United European Gastroenterology Federation (UEGF) Meeting Vienna Austria 2008 pp. OP397."},{"key":"e_1_2_15_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04041.x"},{"key":"e_1_2_15_84_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00360.2002"},{"key":"e_1_2_15_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03730.x"},{"key":"e_1_2_15_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.07.011"},{"key":"e_1_2_15_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02685.x"},{"key":"e_1_2_15_88_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.110858"},{"key":"e_1_2_15_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03566.x"},{"key":"e_1_2_15_90_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0723-6"},{"key":"e_1_2_15_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.295"},{"key":"e_1_2_15_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.060"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04153.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04153.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:07:39Z","timestamp":1698782859000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04153.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,2]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04153.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04153.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,2]]}}}